Fennec Pharmaceuticals Inc.
FENC
Rank in Stocks
#13535
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading... Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Share Price
$10.90
Last synced: 2026-11-12
Market Cap
$382.72M
Change (1 day)
2.44%
Change (1 year)
41.74%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Fennec Pharmaceuticals Inc. (FENC)
Category
Healthcare
EPS for Fennec Pharmaceuticals Inc. (FENC)
EPS as of June 2026 TTM: $-0.13
According to Fennec Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-0.13. At the end of 2025 the company had an EPS of $-0.36, a decrease compared to its 2024 EPS of $-0.02.
EPS history for Fennec Pharmaceuticals Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.13 | -63.89% |
| 2025 | $-0.36 | 2,150.00% |
| 2024 | $-0.02 | -97.33% |
| 2023 | $-0.60 | -36.84% |
| 2022 | $-0.95 | 41.79% |
| 2021 | $-0.67 | -11.84% |
| 2020 | $-0.76 | 20.63% |
| 2019 | $-0.63 | 21.15% |
| 2018 | $-0.52 | 10.64% |
| 2017 | $-0.47 | 113.64% |
| 2016 | $-0.22 | 261.25% |
| 2015 | $-0.06 | -72.32% |
| 2014 | $-0.22 | -215.79% |
| 2013 | $0.19 | -130.16% |
| 2012 | $-0.63 | -206.78% |
| 2011 | $0.59 | -153.15% |
| 2010 | $-1.11 | 13.27% |
| 2009 | $-0.98 | -77.88% |
| 2008 | $-4.43 | -7.32% |
| 2007 | $-4.78 | -71.41% |
| 2006 | $-16.72 | 26.67% |
| 2005 | $-13.20 | -12.23% |
| 2004 | $-15.04 | -24.23% |
| 2003 | $-19.85 | 2.74% |
| 2002 | $-19.32 | 378.22% |
| 2001 | $-4.04 | 35.57% |
| 2000 | $-2.98 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -12,146.15% |
US
|
|
| $-7.07 | 5,338.46% |
US
|
|
| $-5.29 | 3,969.23% |
AU
|
|
| $12.88 | -10,007.77% |
BE
|
|
| $21.56 | -16,684.62% |
NL
|
Questions about Fennec Pharmaceuticals Inc.'s earnings per share (EPS)
What is Fennec Pharmaceuticals Inc.'s earnings per share (EPS)?
Fennec Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-0.13, as of Jun 2026.
What was Fennec Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Fennec Pharmaceuticals Inc.'s earnings per share (EPS) was $-0.36, compared with $-0.02 in 2024.
How has Fennec Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Fennec Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2024 ($-0.02) and lowest in 2022 ($-0.95).
How does Fennec Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Fennec Pharmaceuticals Inc.'s earnings per share (EPS) ($-0.13) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.